Similar to what was observed with pharmacological FoxO1 inhibition, treatment with the GLP-1R agonist, liraglutide, also failed to alleviate DbCM and diastolic dysfunction (decreased E/e′ and increased e′/a′ ratios) in PDHCardiacKO mice with experimental T2D (HFD/low-dose STZ) [108]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.